萊斯康製藥 LXRX 深 滬
已收盤 09-18 16:00:00 美东时间
1.64
+0.020
+1.23%
華盛通- 最 高1.72
- 今 開1.66
- 成交量 284.06万股
- 最 低 1.60
- 昨 收 1.62
- 總市值 4.03亿
- 52周最高 3.73
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 0.92
- 委 比 74.27%
- 總股本 2.46亿
- 歷史最高 22.96
- 量 比 2.00
- 振 幅 7.41%
- 歷史最低 0.92
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexicon Pharmaceuticals announces departure of President, COO Jeff Wade
Lexicon Pharmaceuticals (NASDAQ:LXRX) on Monday said its president and COO, Jeff Wade, is departing the company on or about September 30. The company said that a search for a new COO is underway. Wade...
09-16 20:41
Lexicon Pharmaceuticals Announces Executive Leadership Changes
Lexicon Pharmaceuticals ( ($LXRX) ) has shared an announcement. Jeffrey L. Wade...
09-16 19:18
Lexicon Pharmaceuticals FDA Advisory Committee Meeting For Zynquista, Scheduled For October 31, 2024
Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024 Lexicon Seeks Approval for ZYNQUISTA™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control
08-21 20:06
快讯 | 莱斯康制药宣布为Zynquista召开FDA咨询委员会会议
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
08-21 20:00
快讯 | Lexicon Pharmaceuticals Inc - Pdufa目标日期仍为2024年12月20日
Lexicon Pharmaceuticals Inc - Pdufa Goal Date Remains December 20, 2024
08-21 20:00
Optimized Strategy and Clinical Progress Bolster Buy Rating for Lexicon Pharmaceuticals
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pha...
08-14 00:06
莱斯康制药盘中异动 股价大跌5.36%报1.59美元
北京时间2024年08月10日01时57分，莱斯康制药（LXRX.us）股票出现波动，股价快速下跌5.36%。截至发稿，该股报1.59美元/股，成交量105....
08-10 01:57
Lexicon to present data on sotagliflozin for diabetes, kidney disease
Lexicon Pharmaceuticals (NASDAQ:LXRX) said that efficacy and safety data for its drug sotagliflozin in the treatment of patients with type 1 diabetes and chronic kidney disease will be presented this ...
08-07 22:23
5 Analysts Have This To Say About Lexicon Pharmaceuticals
Throughout the last three months, 5 analysts have evaluated Lexicon Pharmaceuti...
08-03 02:09
快讯 | Lexicon Pharmaceuticals 公司提交文件，申请最高达2亿美元的混合上市权。-SEC 文件
Lexicon Pharmaceuticals Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing
08-02 21:38
